Solving the immunity puzzle takes collaboration among different fields

March 20, 2017
Oral therapeutics developed as a result of modeling the immune system may help sufferers of infections like those caused by E. coli (pictured here in purple). Credit: Virginia Tech

Studying the human immune system is like trying to work a vast, multidimensional jigsaw puzzle with pieces that are constantly changing shape. Billions of microbes interact with the host, shaping the processes that keep us healthy and protected from disease.

Sometimes, however, these interactions do not occur as one would hope, sending the immune system out of synch, causing that can lead to conditions like inflammatory bowel bisease (IBD), diabetes, arthritis, or even cancer.

Millions of Americans suffer from such diseases and incidences are on the rise. Until recently it has been difficult to understand what occurs during these interactions and how they might trigger chronic inflammation.

More importantly, efforts to stop inflammation have produced drugs and treatments that have modest efficacy and side effects nearly as difficult to deal with as the disease itself.

Scientists need to understand how inflammation occurs at the systems level and what might best recalibrate an immune system that has been pushed wildly off course into chronic inflammation. A recent paper in Trends in Immunology explores how the field of immunology can apply modeling approaches to solve the puzzle of immunity.

"By combining computational modeling and immunology experimentation," said Josep Bassaganya-Riera, director of the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) and professor at the Biocomplexity Institute, "we can ensure that we continue to make strides toward that help streamline the process of and move safer, more-effective therapies to patients more quickly."

In the past, different scientific fields have attempted to arrive at answers in a multitude of ways, often with much disagreement. At the Biocomplexity Institute of Virginia Tech, NIMML is taking an integrative approach that transcends existing disciplines—and it's seeing some exciting results.

For instance, current models used by NIMML build on groundbreaking work to uncover new pathways leading to first-in-class therapeutics for IBD.

NIMML has integrated this approach with other forms of modeling and experimentation, allowing them to simulate inflammatory processes at an unprecedented scale. By applying this approach, researchers were able to model clinical responses to new IBD treatments with a high degree of accuracy for simulated patients using machine-learning algorithms.

"Applying modeling approaches to immunology can provide rigorously tested and efficient therapies very quickly with cost-effective use of resources," said Raquel Hontecillas, co-director of NIMML.

In a recent National Institute of Allergy and Infectious Disease workshop, Bassaganya-Riera presented about how solving immunity is a complex process requiring transdisciplinary solutions.

Bassaganya-Riera spoke about the advances precision medicine offers us during Virginia Tech's TEDx event. In his discussion, he explained how modeling and simulation of immunological systems offers clinicians and patients a more rapid pipeline between clinical trials and effective treatments and therapies.

This process also offers a chance for researchers to engage in "the art of the possible," using modeling to demonstrate the promise of new therapies even before they are tested in a living system. Building on these early successes, it is clear that collaboration between modelers and experimentalists will be key to ushering in an era of precision medicine.

Explore further: Novel therapy for Crohn's disease discovered

More information: Yoram Vodovotz et al. Solving Immunology?, Trends in Immunology (2017). DOI: 10.1016/j.it.2016.11.006

Related Stories

Novel therapy for Crohn's disease discovered

March 19, 2012
The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn's disease, a ...

Botanical compound could prove crucial to healing influenza

July 18, 2012
Building on previous work with the botanical abscisic acida, researchers in the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) have discovered that abscisic acid has anti-inflammatory effects in the lungs ...

How to model the immune system—10 billion components at a time

November 4, 2015
The complexity of the human immune response has been difficult to characterize on a 'big picture' level, but researchers at the Virginia Bioinformatics Institute at Virginia Tech have written the book on how it can be done.

C. diff scientists reveal potential target to fight infections

November 30, 2012
Researchers at Virginia Bioinformatics Institute at Virginia Tech have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.

Researchers test 'smart' simulations to analyze unknown variables in immune response

November 6, 2015
Technology to predict how our bodies will manage chronic diseases such as Crohn's disease and inflammatory bowel disease promises to accelerate the discovery of new treatments, identify leads for further study, and occasionally ...

Recommended for you

The immune cells that help tumors instead of destroying them

December 12, 2017
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...

Cancer gene plays key role in cystic fibrosis lung infections

December 12, 2017
PTEN is best known as a tumor suppressor, a type of protein that protects cells from growing uncontrollably and becoming cancerous. But according to a new study from Columbia University Medical Center (CUMC), PTEN has a second, ...

Researchers bring new insight into Chediak-Higashi syndrome, a devastating genetic disease

December 12, 2017
A team of researchers from the National Institutes of Health and University of Manchester have uncovered new insights into a rare genetic disease, with less than 500 cases of the disease on record, which devastates the lives ...

Drug increases speed, safety of treatment for multiple food allergies

December 11, 2017
In a randomized, controlled phase-2 clinical trial, an asthma medication increased the speed and safety of a protocol used to treat children for several food allergies at once, according to a study by researchers at the Stanford ...

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

December 9, 2017
Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening ...

Location, location, location: Immunization delivery site matters

December 1, 2017
In vaccination, a certain subpopulation of dendritic cells is vital to triggering the body's adaptive immune system, report researchers at The Jackson Laboratory (JAX), Yale University and Astra-Zeneca.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.